Dr. Pearl Mary Varughese
Pediatrics Neonatal Health and Biochemistry Neonatal Respiratory Health Research Pediatric research Serum bilirubin Kernicterus Nomogram Complementary and alternative medicine Pediatrics, Perinatology and Child Health Pulmonary and Respiratory Medicine

Bio

Dr. Pearl Mary Varughese is a dedicated pediatrician and researcher based in Kerala, India. She earned her MBBS and MD in Pediatrics from the Pondicherry Institute of Medical Sciences. Her research focuses on neonatal jaundice and transcutaneous bilirubinometry, with notable publications including 'Can we Rely on Transcutaneous Bilirubinometry during Phototherapy?' and 'Krameros Scale or Transcutaneous Bilirubinometry: The Ideal Choice of a Pediatrician?'. With 15 publications, 20 citations, an h-index of 2, and an i10-index of 1, she actively contributes to pediatric research. She is a fellow of the Global Journal of Medical Research and holds an ORCID iD, reflecting her commitment to advancing medical knowledge.

Educational Journey

Pondicherry Institute of Medical Sciences Pondicherry India

MBBS, MD • Pediatrics

Experience

Pondicherry Institute of Medical Sciences Pondicherry India

0 - 0

Institute of Medical Sciences

0 - 0

Grants and Awards

FELLOWSHIP

Fellow

2020 6800 USD

Research

Can we Rely on Transcutaneous Bilirbinometry during Phototherapy?

Article May 9, 2020

Background: Neonatal jaundiceis one of the main reasons for prolonged hospitalization in newborns, and its progress and treatment depends on serum bilirubin values. Phototherapy remains the mainstay of treatment of pathological jaundice in newborn babies. Though, transcutaneous bilirubinometer has been used as a screening device for measuring bilirubin, its role during phototherapy has always been questioned. Objective: To study the correlation between Transcutaneous bilirubinometer (TcB) values with serum bilirubin levels (TSB) in infants during phototherapy in term and late preterm babies. Materials and Methods: The study was conducted in a tertiary new-born center from November 2014 to June 2016. The inclusion criteria included all babies above 34 weeks gestation and exclusion criteria included babies with established direct hyperbilirubinemia, neonatal septicemia, major congenital/ gastrointestinal malformations, and those on phototherapy